1. 1332 UREAPLASMA UREALYTICUM AND NEWBORN RESPIRATORY DISTRESS
- Author
-
Albert Bartoletti, M. L. Lepow, Richard A. Venezia, Susan St Martin, and Sally Hipp
- Subjects
Mechanical ventilation ,medicine.medical_specialty ,Fetus ,Pediatrics ,Respiratory distress ,business.industry ,Obstetrics ,medicine.medical_treatment ,Newborn respiratory distress ,Erythromycin ,medicine.disease_cause ,Umbilical cord ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Medicine ,Respiratory system ,business ,Ureaplasma urealyticum ,medicine.drug - Abstract
Ureaplasma urealyticum (Uu) commonly inhabits the vaginal tract of pregnant women and is known to be transmitted to the fetus and newborn. Tissue invasiveness by this organism has been suspected on the basis of the association between its presence and PMN infiltration of placental membranes, fetal surfaces and umbilical cord. This on-going study provides data concerning incidence, duration of positive culture, and clinical course of newborn infants with respiratory distress (RD) whose respiratory tracts are inhabited by this organism. To date, 65 infants GA 24-42 weeks with RD requiring mechanical ventilation (MV) had tracheal aspirate (TA) collected for Uu. 13 infants (20%) were positive. 1 infant remained positive after completion of erythromycin therapy. 6 of 10 infants that grew Uu had 2 or more TA's. 3 of 10 that grew Uu expired. 4 of 7 survivors and 1 of 3 who expired developed chronic lung disease (CLD) as defined by the need for MV and/or O2 > 30 days. The 3 survivors who did not develop CLD required MV and/or supplemental O2 for 4-23 days. Uu is commonly found in the respiratory tracts of critically ill infants with RD and persists for weeks. Its pathogenicity and the clinical course of infants who have antimicrobial therapy directed specifically towards this organism remain to be determined.
- Published
- 1985
- Full Text
- View/download PDF